BioHarvest Sciences Gestione

Gestione criteri di controllo 4/4

BioHarvest Sciences Il CEO è Ilan Sobel, nominato in Jun2020, ha un mandato di 4.42 anni. possiede direttamente 1.25% delle azioni della società, per un valore di € 968.15K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.4 anni e 3.8 anni.

Informazioni chiave

Ilan Sobel

Amministratore delegato

US$481.6k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	4.4yrs
Proprietà del CEO	1.3%
Durata media del management	4.4yrs
Durata media del Consiglio di amministrazione	3.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Ilan Sobel

4.4yrs

Mandato

US$481,581

Compensazione

Mr. Ilan Sobel has been the Chief Executive Officer at BioHarvest Sciences Inc. since June 9, 2020. He served as Chief Operating Officer at Weissbeerger Ltd. and then Chief Commercial Officer of Weissbeerg...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Zaki Rakib	Co-Founder	6.2yrs	US$1.16m	Nessun dato
Ilan Sobel	Chief Executive Officer	4.4yrs	US$481.58k	1.25% € 968.2k
Yochi Hagay	Co-Founder	6.2yrs	US$67.02k	0.18% € 141.5k
Alan Rootenberg	Chief Financial Officer	6.1yrs	US$31.48k	0.0078% € 6.1k
Ilana Belzer	Chief Operating Officer	1.6yrs	US$275.09k	0.0032% € 2.4k
David Ryan	VP of Investor Relations & Secretary	11.6yrs	US$44.45k	0.23% € 174.2k
Brian Cornblatt	Chief Medical Officer & Member of Scientific Advisory Board	2.7yrs	US$421.35k	0.015% € 11.5k
Matthew Zrebiec	Vice President of Business Development	less than a year	Nessun dato	Nessun dato

4.4yrs

Durata media

65yo

Età media

Gestione esperta: Il team dirigenziale di 8MV0 è considerato esperto (durata media dell'incarico 4.4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Zaki Rakib	Co-Founder	6.2yrs	US$1.16m	Nessun dato
Yochi Hagay	Co-Founder	3.8yrs	US$67.02k	0.18% € 141.5k
Brian Cornblatt	Chief Medical Officer & Member of Scientific Advisory Board	1.8yrs	US$421.35k	0.015% € 11.5k
Steven Lehrer	Member of Board of Advisor	3.1yrs	Nessun dato	Nessun dato
Vincent Giampapa	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Dennis Goodman	Member of Scientific Advisory Board	3.8yrs	Nessun dato	Nessun dato
David Tsur	Independent Non-Executive Director	3.1yrs	US$37.36k	Nessun dato
David Brady	Member of Scientific Advisory Board	4.1yrs	Nessun dato	Nessun dato
Scott McCune	Member of Advisory Board	3.7yrs	Nessun dato	Nessun dato
Vivien Rakib	Independent Director	6.2yrs	US$26.65k	17.5% € 13.5m
John Fiddick	Independent Director	5.8yrs	US$26.65k	Nessun dato
Roberto Chait	Member of Advisory Board	4.1yrs	Nessun dato	Nessun dato

3.8yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 8MV0 sono considerati esperti (durata media dell'incarico 3.8 anni).

BioHarvest Sciences Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Bioharvest Sciences Inc. Announces Resignation of David Ryan as Director

BioHarvest Sciences Inc., Annual General Meeting, May 27, 2024

BioHarvest Sciences Inc. Announces Appointment of John Paul Sangiovanni as Medical and Scientific Advisory Board

BioHarvest Sciences Inc., Annual General Meeting, Jul 19, 2023

Bioharvest Sciences Inc. Appoints George Garibaldi to its Scientific Board of Advisors

No independent directors

Recent updates

BioHarvest Sciences Inc. to Report Q3, 2024 Results on Nov 14, 2024

Bioharvest Sciences Inc. Announces Resignation of David Ryan as Director

Second quarter 2024 earnings released: US$0.042 loss per share (vs US$0.21 loss in 2Q 2023)

New minor risk - Market cap size

BioHarvest Sciences Inc. announced that it expects to receive CAD 6.847977 million in funding

First quarter 2024 earnings released: US$0.48 loss per share (vs US$0.057 loss in 1Q 2023)

Full year 2023 earnings released: US$0.027 loss per share (vs US$0.025 loss in FY 2022)

BioHarvest Sciences Inc., Annual General Meeting, May 27, 2024

BioHarvest Sciences Inc. to Report Q4, 2023 Results on Mar 29, 2024

BioHarvest Sciences Inc. announced that it has received CAD 13.622872 million in funding

Bioharvest Sciences Inc. Announces Major Product Launch of Vinia-Based Functional Coffee Products

Third quarter 2023 earnings released: US$0.004 loss per share (vs US$0.009 loss in 3Q 2022)

Bioharvest Sciences Inc. Revises Revenue Guidance for the Year 2023

BioHarvest Sciences Inc. announced that it expects to receive CAD 12 million in funding

Second quarter 2023 earnings released: US$0.006 loss per share (vs US$0.005 loss in 2Q 2022)

BioHarvest Sciences Inc. to Report Q2, 2023 Results on Aug 30, 2023

BioHarvest Sciences Inc. announced that it expects to receive CAD 4.625103 million in funding

BioHarvest Sciences Inc. Announces Appointment of John Paul Sangiovanni as Medical and Scientific Advisory Board

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.005 loss in 1Q 2022)

Bioharvest Sciences Inc. Reiterated Sales Guidance for the year 2023

BioHarvest Sciences Inc., Annual General Meeting, Jul 19, 2023

Full year 2022 earnings released: US$0.025 loss per share (vs US$0.023 loss in FY 2021)

BioHarvest Sciences Inc. Announces Clinical Study in Patients with Multiple Sclerosis-Related Optic Neuritis

Bioharvest Sciences Inc. Appoints George Garibaldi to its Scientific Board of Advisors

BioHarvest Sciences Inc. announced that it has received CAD 10.03355 million in funding

Bioharvest Sciences Inc. Provides Revenue Guidance for the Year 2022 and 2023

Third quarter 2022 earnings released: US$0.009 loss per share (vs US$0.007 loss in 3Q 2021)

No independent directors

Second quarter 2022 earnings released: US$0.005 loss per share (vs US$0.004 profit in 2Q 2021)

BioHarvest Sciences Inc. Appoints Gavriel Lambert to its Board of Advisors

Bioharvest Sciences Inc. Hires Dr. Brian S. Cornblatt as Chief Medical Officer

First quarter 2022 earnings released: US$0.005 loss per share (vs US$0.016 loss in 1Q 2021)

Full year 2021 earnings released: US$0.023 loss per share (vs US$0.019 loss in FY 2020)

No independent directors

BioHarvest Sciences Inc. announced that it expects to receive CAD 6.3 million in funding

BioHarvest Sciences Inc. Reiterates Sales Orders Guidance for 2022

BioHarvest Sciences Inc. Provides Revenue Guidance for the Year 2022

Third quarter 2021 earnings: Revenues in line with analyst expectations

Second quarter 2021 earnings released: EPS US$0.004 (vs US$0.004 loss in 2Q 2020)

Bioharvest Sciences Inc. Unveils New Groundbreaking Cannabis Trichome Structure

BioHarvest Sciences Inc. announced that it expects to receive CAD 4 million in funding

BioHarvest Sciences Inc. Reveals Vinia Anti-Aging Capabilities Via Blood Flow Improvement

First quarter 2021 earnings released

Full year 2020 earnings released

Bioharvest Sciences Inc. Unveils Unique Polyphenolic Content of Its Upcoming Olive Based Nutraceutical

Bioharvest Sciences Inc. Announces Partnership with Boldt and Summit Strategy Group to Develop A Sustainability Framework and Esg Report

BioHarvest Sciences Inc. Announces a Major Breakthrough in the Growth of Cannabis TRICHOMES across Multiple Strains in Liquid Media

BioHarvest Sciences Inc. announced that it has received CAD 6.179932 million in funding

BioHarvest Sciences Inc. announced that it expects to receive CAD 6 million in funding

BioHarvest Sciences Inc. Appoints Dennis Goodman to Its Scientific Advisory Board

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media